Claudio Ferri
L'Aquila University, Italy

Articles in Scholarly Journals [Incomplete List]

  1. Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine
    Advances in Therapy, vol. 25, no. 4, pp. 300–320, 2008
  2. Enhanced soluble CD40 ligand and Alzheimer's disease: Evidence of a possible pathogenetic role
    Neurobiology of Aging, vol. 29, no. 3, pp. 348–356, 2008
  3. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction
    Atherosclerosis, vol. 196, no. 1, pp. 313–319, 2008
  4. Different Effects of Angiotensin Converting Enzyme Inhibitors on Endothelin-1 and Nitric Oxide Balance in Human Vascular Endothelial Cells: Evidence of an Oxidant-Sensitive Pathway
    Mediators of Inflammation, vol. 2008, Article ID 305087, 7 pages, 2008
  5. Conceptual basis and methodology of the SOPHIA study
    Pharmacogenomics, vol. 8, no. 11, pp. 1497–1509, 2007
  6. COX-2: Friend or Foe?
    Current Pharmaceutical Design, vol. 13, no. 16, pp. 1715–1721, 2007
  7. C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
    Current Pharmaceutical Design, vol. 13, no. 16, pp. 1631–1645, 2007
  8. Comparison of the Captopril and the Saline Infusion Test for Excluding Aldosterone-Producing Adenoma
    Hypertension, vol. 50, no. 2, pp. 424–431, 2007
  9. Enhanced Plasma Soluble CD40 Ligand Levels in Essential Hypertensive Patients With Blunted Nocturnal Blood Pressure Decrease
    American Journal of Hypertension, vol. 20, no. 1, pp. 70–76, 2007
  10. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma
    Journal of Hypertension, vol. 25, no. 7, pp. 1433–1442, 2007
  11. A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients
    Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2293–2300, 2006
  12. Cocoa beans, endothelial function and aging: an unexpected friendship?
    Journal of Hypertension, vol. 24, no. 8, p. 1471???1474, 2006
  13. Renal Damage in Primary Aldosteronism: Results of the PAPY Study
    Hypertension, vol. 48, no. 2, pp. 232–238, 2006
  14. Nonpharmacological Treatment of Hypercholesterolemia Increases Circulating Endothelial Progenitor Cell Population in Adults
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. e38–e39, 2006
  15. Commentary and Discussion on the Opening Session Epidemiology, Cardiovascular Aspects, and Analysis of Cocoa Flavanols
    Journal of Cardiovascular Pharmacology, vol. 47, no. Supplement 2, pp. S119–S121, 2006
  16. Early Activation of Vascular Endothelial Cells and Platelets in Obese Children
    Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 6, pp. 3145–3152, 2005
  17. Endothelial function and dysfunction. Part I
    Journal of Hypertension, vol. 23, no. 1, pp. 7–17, 2005
  18. Cocoa Reduces Blood Pressure and Insulin Resistance and Improves Endothelium-Dependent Vasodilation in Hypertensives
    Hypertension, vol. 46, no. 2, pp. 398–405, 2005
  19. Endothelial Activation. Sliding Door to Atherosclerosis
    Current Pharmaceutical Design, vol. 11, no. 17, pp. 2163–2175, 2005
  20. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control
    Diabetologia, vol. 48, no. 6, pp. 1216–1224, 2005
  21. Treatment of hypertension and adherence to treatment guidelines in clinical practice: An Italian study
    Advances in Therapy, vol. 22, no. 2, pp. 96–106, 2005
  22. Does nondipping blood pressure profile contribute to vascular inflammation during sleep deprivation?
    Journal of the American College of Cardiology, vol. 44, no. 7, pp. 1529–1530, 2004
  23. ENDOTHELIAL CELL ACTIVATION IN MEN WITH ERECTILE DYSFUNCTION WITHOUT CARDIOVASCULAR RISK FACTORS AND OVERT VASCULAR DAMAGE
    The Journal of Urology, vol. 171, no. 4, pp. 1601–1604, 2004
  24. Bezafibrate and Simvastatin: Different Beneficial Effects for Different Therapeutic Aims
    Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 4, pp. 1978–1978, 2004
  25. Genetic Determinants of Nonmodulating Hypertension
    Hypertension, vol. 42, no. 5, pp. 901–908, 2003
  26. Angiotensin II Inhibits Endothelial Cell Motility Through an AT1-Dependent Oxidant-Sensitive Decrement of Nitric Oxide Availability
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1218–1223, 2003
  27. Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty
    Circulation, vol. 108, no. 22, pp. 2776–2782, 2003
  28. Effects of Bezafibrate and Simvastatin on Endothelial Activation and Lipid Peroxidation in Hypercholesterolemia: Evidence of Different Vascular Protection by Different Lipid-Lowering Treatments
    Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 11, pp. 5341–5347, 2003
  29. Journal of Hypertension, vol. 21, no. 5, pp. 951–959, 2003
  30. Mediterranean diet, cocoa and cardiovascular disease
    Journal of Hypertension, vol. 21, no. 12, pp. 2231–2234, 2003
  31. Effects of Obesity and Weight Loss on Soluble CD40L Levels
    JAMA: The Journal of the American Medical Association, vol. 289, no. 14, pp. 1781–1782, 2003
  32. l-arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in Type II diabetic patients
    Diabetologia, vol. 45, no. 8, pp. 1120–1127, 2002
  33. Prolonged, low dose α-tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation
    Clinica Chimica Acta, vol. 319, no. 1, p. 0, 2002
  34. Patterns of Myocardial Endothelin-1 Expression and Outcome After Cardiac Transplantation
    Circulation, vol. 105, no. 15, pp. 1768–1771, 2002
  35. Vitamin E Supplementation Reduces Plasma Vascular Cell Adhesion Molecule-1 and von Willebrand Factor Levels and Increases Nitric Oxide Concentrations in Hypercholesterolemic Patients
    Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 6, pp. 2940–2945, 2002
  36. The Influences of Obesity and Glycemic Control on Endothelial Activation in Patients with Type 2 Diabetes
    Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 11, pp. 5491–5497, 2001
  37. Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild essential hypertension
    American Journal of Hypertension, vol. 14, no. 3, pp. 224–230, 2001
  38. Blood endothelin-1 levels before and after carotid endoarterectomy for atherosclerotic stenosis
    Atherosclerosis, vol. 154, no. 1, pp. 137–140, 2001
  39. Circulating vascular endothelial growth factor levels are decreased in patients with chronic hepatitis and liver cirrhosis depending on the degree of hepatic damage
    Clinical Science, vol. 99, no. 2, p. 159, 2000
  40. High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients
    Kidney International, vol. 56, no. 4, pp. 1499–1504, 1999
  41. Effects of insulin on in vitro vascular cell adhesion molecule-1 expression and in vivo soluble VCAM-1 release
    Diabetologia, vol. 42, no. 10, pp. 1235–1239, 1999
  42. Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels
    Clinical Science, vol. 96, no. 3, p. 261, 1999
  43. Decreased activity of the red blood cell ATPase-dependent Na+ pump in patients with cardiac syndrome X
    Clinical Science, vol. 97, no. 3, p. 369, 1999
  44. Effects of naloxone on myocardial ischemic preconditioning in humans☆
    Journal of the American College of Cardiology, vol. 33, no. 7, pp. 1863–1869, 1999
  45. Relationship between insulin resistance and nonmodulating hypertension: linkage of metabolic abnormalities and cardiovascular risk
    Diabetes, vol. 48, no. 8, pp. 1623–1630, 1999
  46. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities
    Diabetes, vol. 47, no. 4, pp. 660–667, 1998
  47. Enhanced activity of sodium–lithium countertransport in patients with cardiac syndrome X☆A potential link between cardiac and metabolic syndrome X
    Journal of the American College of Cardiology, vol. 32, no. 7, pp. 2031–2034, 1998
  48. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes
    Diabetologia, vol. 41, no. 11, pp. 1392–1396, 1998
  49. Influence of reduced glutathione infusion on glucose metabolism in patients with non?insulin-dependent diabetes mellitus*1
    Metabolism, vol. 47, no. 8, pp. 993–997, 1998
  50. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy
    American Journal of Hypertension, vol. 11, no. 8, pp. 983–988, 1998
  51. Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities
    Diabetologia, vol. 40, no. 1, pp. 100–102, 1997
  52. ENDOTHELIN-1 IN DIABETIC AND NONDIABETIC MEN WITH ERECTILE DYSFUNCTION
    The Journal of Urology, vol. 158, no. 5, pp. 1770–1774, 1997
  53. Polyol pathway activation and glutathione redox status in non?insulin-dependent diabetic patients*1
    Metabolism, vol. 46, no. 10, pp. 1194–1198, 1997
  54. Effect of Aprotinin on Insulin Sensitivity in Non-insulin-dependent Diabetes Mellitus
    Diabetic Medicine, vol. 13, no. 7, pp. 642–645, 1996
  55. To the editor
    Metabolism, vol. 44, no. 5, pp. 689–690, 1995
  56. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis
    The American Journal of Medicine, vol. 99, no. 3, pp. 255–260, 1995
  57. Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patientsInfluence of ACE inhibition
    American Journal of Hypertension, vol. 8, no. 1, pp. 40–47, 1995
  58. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo
    Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 3, pp. 829–835, 1995
  59. Circulating endothelin-1 concentrations in patients with chronic hypoxia.
    Journal of Clinical Pathology, vol. 48, no. 6, pp. 519–524, 1995
  60. Effects of Atrial Natriuretic Factor Infusion on Plasma Prorenin Levels in Hypertensive Males
    Clinical and Experimental Hypertension, vol. 16, no. 3, pp. 283–302, 1994
  61. Urinary kallikrein and salt sensitivity in essential hypertensive males
    Kidney International, vol. 46, no. 3, Article ID ki1994333, 8 pages, 1994
  62. Enhanced release of atrial natriuretic factor during exercise-induced myocardial ischaemia in patients after acute myocardial infarction
    International Journal of Cardiology, vol. 34, no. 2, pp. 179–187, 1992
  63. Effect of angiotensin converting enzyme inhibition on platelet angiotensin II content
    The American Journal of Medicine, vol. 84, no. 3, pp. 119–121, 1988